| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.038 | 0.4 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.4 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.4 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.4 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | necrostatin-1 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |